Normosang (Human Hemin)

Human hemin provides a source of heme that feeds back to inhibit the enzyme ALA synthase, the first and rate‑limiting step in the heme biosynthetic pathway. By down‑regulating this enzyme, the drug reduces the accumulation of aminolevulinic acid and porphobilinogen, which are responsible for the neurotoxic symptoms of acute porphyria attacks.

The dosing regimen for Normosang is individualized by the treating physician based on the severity of the porphyria attack, patient weight, and clinical response. The prescriber determines the amount of lyophilized powder to reconstitute, the infusion rate, and the total number of doses required for each acute episode.

Safety data for human hemin in pregnant or lactating women are limited, and the product is generally classified as use‑only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate the risk‑benefit ratio and consider alternative therapies when possible.

To request Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

The main alternative to human hemin is the use of high‑dose glucose infusion, which can suppress ALA synthase indirectly. Human hemin provides a more direct and rapid inhibition of porphyrin precursor synthesis, often resulting in faster symptom relief. However, both therapies may be used sequentially or together depending on clinical judgment.

Normosang should be stored at 2‑8 °C in a refrigerator. The vial must be kept in its original packaging, protected from light, and should never be frozen or shaken. If the product is to be transported, maintain the cold‑chain conditions until reconstitution.

Normosang is supplied as a lyophilized powder that must be reconstituted with a compatible diluent to form a sterile solution. The solution is then administered intravenously over a period of 30‑60 minutes under medical supervision, with vital signs monitored before, during, and after the infusion.

The most critical adverse events include anaphylactic or severe allergic reactions, hemolysis leading to rapid anemia, and acute renal impairment. Prompt recognition of these signs and immediate medical intervention are essential to mitigate morbidity and mortality.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any excipients in the formulation. Caution is also advised for individuals with severe hepatic or renal failure, uncontrolled iron overload, or those receiving other heme‑containing products, as the risk of adverse effects may be heightened.